1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
- Contribution to journal › Article
-
Mark
A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
- Contribution to journal › Article
- 2021
-
Mark
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
- Contribution to journal › Article
- 2019
-
Mark
Protection of Kidney Function with Human Antioxidation Protein α
1
-Microglobulin in a Mouse
177
Lu-DOTATATE Radiation Therapy Model
- Contribution to journal › Article
- 2017
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
- Contribution to journal › Article
